Current Environment:


This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product (eli-cel) in a parent clinical study. After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.


Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)

Recruitment Status

Active, not recruiting

Eligibility Criteria

Inclusion Criteria:

Provision of written informed consent for this study by the participant or participant's parent(s)/ legal guardian(s) and written informed assent by participant, if applicable
Have received eli-cel in a parent clinical study

Exclusion Criteria:

There are no exclusion criteria for this study


Intervention Type

Intervention Name


Lenti-D Drug Product



Min Age


Max Age

17 Years

Download Date

September 8, 2023

Principal Investigator


Primary Contact Information

For more information on this trial, visit


For more information and to contact the study team:

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product NCT02698579